TL;DR
This study identifies the transcription factor Yin Yang 1 (YY1) as a key regulator of TREM2 expression in microglia. They demonstrate that YY1 directly binds to the TREM2 promoter, and its downregulation, observed in both inflammatory conditions and Alzheimer's disease models, leads to reduced TREM2 levels. This suggests targeting YY1 could be a therapeutic strategy for Alzheimer's disease.
What Problem Does This Paper Address?
Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by amyloid plaques and tau tangles. Microglia, the brain's immune cells, play a crucial role in clearing these pathological hallmarks, and the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is a key receptor expressed on microglia involved in this process. Genetic studies have linked mutations in the TREM2 gene to an increased risk of AD, suggesting that impaired TREM2 function contributes to the disease. However, the precise mechanisms regulating TREM2 expression, particularly the transcription factors involved, remained largely unknown. This paper aims to uncover these regulatory mechanisms, focusing on how TREM2 expression is controlled and how this control might be disrupted in AD.
Methods
The researchers employed a multi-pronged approach to identify and characterize the regulatory role of YY1 in TREM2 expression:
- Luciferase Reporter Assays: They constructed a series of deletion fragments of the human TREM2 promoter and cloned them into a luciferase reporter vector. By transfecting these constructs into microglial (BV2) and neuroblastoma (Neuro2A) cell lines, they could measure the transcriptional activity of different promoter regions and pinpoint the minimal active region.
- In Silico Prediction: Computational tools were used to predict potential transcription factor binding sites within the TREM2 promoter.
- DNA Pull-Down Assays: Biotinylated DNA fragments of the TREM2 promoter were used to capture proteins from microglial nuclear extracts. Mass spectrometry was then used to identify the proteins that specifically bound to these fragments.
- Electrophoretic Mobility Shift Assay (EMSA): This technique was used to confirm the direct binding of YY1 to the predicted binding site on the TREM2 promoter. They used labeled DNA probes and nuclear extracts, observing shifts in band migration when YY1 was present. Competition assays with unlabeled wild-type and mutant probes helped confirm specificity.
- Western Blotting: This technique was used to detect and quantify protein levels of YY1 and TREM2 in various experimental conditions, including shRNA-mediated silencing of YY1, LPS treatment, and in AD model mice.
- shRNA-mediated Silencing: Short hairpin RNAs (shRNAs) were used to specifically knock down the expression of YY1 in cell lines to assess its impact on TREM2 expression and promoter activity.
Datasets
Not discussed in the paper. The study primarily utilizes cell lines (BV2, Neuro2A, HEK293) and mouse models (APP/PS45 AD model mice).
Key Insights and Ideas
- TREM2 Promoter Complexity: The TREM2 promoter contains both positive and negative regulatory elements, with a critical activating region located between -370 and -118 base pairs upstream of the transcription start site.
- YY1 as a Direct TREM2 Regulator: The study definitively identifies YY1 as a transcription factor that directly binds to a specific element within the minimal TREM2 promoter. This binding is crucial for driving TREM2 expression.
- Conservation of YY1 Regulation: The presence of a conserved YY1 response element in the TREM2 promoter across multiple species suggests that this regulatory mechanism is evolutionarily important.
- YY1 and TREM2 Downregulation in AD Contexts: Both YY1 and TREM2 expression are found to be reduced in response to inflammatory stimuli (LPS) and in the brains of AD model mice. This parallel downregulation highlights a potential link between inflammation, YY1, and TREM2 deficiency in AD pathogenesis.
- Therapeutic Potential of YY1: The findings strongly suggest that maintaining or enhancing microglial YY1 levels could be a viable strategy for preserving TREM2 expression and potentially mitigating AD pathology.
Key Results
- Deletion analysis of the TREM2 promoter revealed a critical activating region between -370 and -118 bp.
- DNA pull-down assays and in silico predictions identified YY1 as a strong candidate transcription factor binding to this region.
- EMSA and DNA pull-down assays confirmed direct binding of YY1 to the TREM2 promoter.
- shRNA-mediated silencing of YY1 significantly reduced TREM2 promoter activity and TREM2 protein levels in BV2 and Neuro2A cells.
- In BV2 cells, YY1 silencing led to a ~30% reduction in TREM2, while in Neuro2A cells, it caused a >70% decrease.
- LPS treatment of BV2 cells downregulated both YY1 and TREM2 protein levels.
- In APP/PS45 AD model mice, both YY1 and TREM2 were significantly decreased compared to wild-type mice.
Limitations and Future Work
- YY1 Overexpression Challenges: The authors note that overexpressing functional YY1 in BV2 cells, especially under LPS treatment, was extremely weak, limiting their ability to fully rescue TREM2 expression in that context. This suggests that other factors might be involved in the complex regulation of YY1 activity or TREM2 expression under inflammatory conditions.
- In Vivo Rescue Experiments: While the study shows YY1 and TREM2 are downregulated in AD model mice, direct in vivo experiments demonstrating that restoring YY1 levels can rescue TREM2 expression and ameliorate AD pathology are not presented.
- Mechanism of YY1 Repression: The paper identifies a repressing cis-element between -580 and -370 bp of the TREM2 promoter. Further investigation into the factors that bind to this region and their interplay with YY1 could provide a more complete picture of TREM2 regulation.
- Therapeutic Strategy Development: The authors propose targeting microglial YY1 for AD prevention and therapy. Future work would involve developing specific strategies to enhance YY1 activity or expression in microglia in vivo, and rigorously testing their efficacy in preclinical AD models. Investigating how YY1's role might differ in different microglial states or disease stages would also be valuable.
Summary updated